Hiserodt, John

Hiserodt, John was paid $6.30M by Medicaid between Jan 2018 and Nov 2024, across 193 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 21% of everything it billed.

Compared with peers

Next to other Cytopathology Physician providers in California

Rank by total paid#3 of 69

Median peer was paid$50K

This provider vs. median125×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	505	$7K
2019	6,663	$288K
2020	1,913	$97K
2021	350	$8K
2022	33,900	$822K
2023	142,772	$3.18M
2024incomplete	115,574	$1.89M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	21%	16,281	11,199	$1.32M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	16%	4,832	4,641	$1.03M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.8%	13,077	7,449	$366K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	5.0%	2,526	1,532	$316K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	4.4%	4,230	3,469	$276K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	2.5%	4,144	3,986	$155K
87631		2.1%	4,208	4,053	$133K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.8%	6,750	6,672	$115K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.8%	7,355	7,326	$114K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.7%	6,848	6,770	$110K
87486		1.4%	4,253	4,101	$89K
80061	Lipid panel	1.3%	11,036	10,990	$84K

181 more codes

84443	Thyroid stimulating hormone (TSH)	1.3%	8,755	$83K
80053	Comprehensive metabolic panel	1.3%	12,419	$83K
87634		1.2%	2,614	$78K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	1,794	$76K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	1.2%	3,140	$74K
87581		1.2%	4,243	$73K
87541		1.1%	4,240	$72K
86003		<1%	645	$57K
83036	Hemoglobin; glycosylated (A1C)	<1%	9,830	$56K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	12,774	$55K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	4,498	$52K
86235		<1%	746	$50K
80074		<1%	2,077	$44K
84403		<1%	2,373	$41K
87505		<1%	534	$40K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,023	$38K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,670	$33K
86481		<1%	789	$33K
84402		<1%	1,796	$32K
84153		<1%	2,448	$30K
86696		<1%	2,771	$30K
86780		<1%	4,484	$30K
84270		<1%	1,798	$27K
87077		<1%	5,687	$27K
82670		<1%	1,411	$26K
88112		<1%	555	$26K
87150		<1%	173	$26K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,771	$26K
82607		<1%	3,108	$25K
87086	Culture, bacterial; quantitative colony count, urine	<1%	6,478	$25K
82172		<1%	1,131	$25K
84481		<1%	2,222	$24K
82652		<1%	902	$24K
87481		<1%	1,248	$22K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,332	$21K
82627		<1%	1,098	$20K
99213	Doctor's office visit, returning patient (routine)	<1%	395	$19K
82728		<1%	2,651	$19K
86695		<1%	2,637	$19K
82746		<1%	1,812	$19K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	501	$19K
84154		<1%	1,552	$19K
86803		<1%	2,238	$18K
88142		<1%	1,742	$16K
87653		<1%	757	$16K
83090		<1%	984	$16K
84146		<1%	1,318	$15K
84305		<1%	881	$15K
87640		<1%	761	$15K
87340		<1%	2,608	$15K
83001		<1%	1,379	$14K
82533		<1%	969	$14K
87480		<1%	632	$14K
84144		<1%	888	$14K
83002		<1%	1,314	$14K
87088		<1%	3,334	$12K
83003		<1%	893	$12K
81001		<1%	4,539	$11K
83013		<1%	519	$11K
87500		<1%	546	$11K
84550		<1%	3,207	$11K
87506		<1%	70	$10K
87070		<1%	2,009	$9K
83540		<1%	2,113	$9K
84439		<1%	1,681	$9K
83550		<1%	1,760	$8K
83525		<1%	924	$8K
87563		<1%	652	$8K
96156		<1%	188	$8K
83695		<1%	862	$8K
87184		<1%	3,343	$8K
83010		<1%	874	$8K
87511		<1%	488	$8K
82610		<1%	620	$7K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	495	$7K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	167	$7K
82523		<1%	487	$7K
84702		<1%	1,044	$7K
84466		<1%	764	$7K
86140		<1%	1,653	$7K
86038		<1%	951	$6K
83690		<1%	1,180	$6K
80081		<1%	231	$6K
82550		<1%	1,082	$6K
83735		<1%	1,172	$6K
82785		<1%	655	$6K
82150		<1%	1,083	$5K
82248		<1%	1,433	$5K
86225		<1%	669	$5K
84480		<1%	702	$5K
87081		<1%	1,214	$4K
86762		<1%	689	$4K
82951		<1%	660	$4K
81002		<1%	2,977	$4K
87660		<1%	458	$4K
87071		<1%	899	$3K
82043		<1%	1,159	$3K
84100		<1%	898	$3K
86430		<1%	866	$3K
85027		<1%	762	$3K
86592		<1%	949	$3K
84436		<1%	723	$3K
81003		<1%	1,397	$3K
87076		<1%	613	$2K
80055		<1%	67	$2K
83516		<1%	155	$2K
82672		<1%	229	$2K
85044		<1%	891	$2K
82105		<1%	51	$2K
85651		<1%	1,106	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	281	$2K
86735		<1%	336	$2K
82570		<1%	616	$2K
85730		<1%	495	$2K
86901		<1%	420	$2K
86787		<1%	351	$2K
86765		<1%	339	$2K
86200		<1%	273	$1K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	202	$1K
86706		<1%	407	$1K
80050	General health panel	<1%	958	$1K
80076		<1%	427	$1K
83655		<1%	211	$1K
85610		<1%	537	$1K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	16	$1K
85007		<1%	666	$1K
86364		<1%	55	$987.29
86664		<1%	104	$967.28
83970		<1%	56	$928.12
99000		<1%	253	$918.39
82947		<1%	353	$913.80
86160		<1%	76	$900.08
87186		<1%	224	$878.93
82679		<1%	62	$850.38
84479		<1%	395	$844.14
82950		<1%	367	$800.40
80069		<1%	135	$693.67
86704		<1%	231	$690.08
86376		<1%	82	$679.48
88313		<1%	18	$644.39
88312		<1%	18	$617.50
86665		<1%	107	$578.18
86900		<1%	422	$576.84
86850		<1%	383	$549.51
83721		<1%	122	$500.58
86060		<1%	153	$494.65
86146		<1%	12	$488.84
86663		<1%	107	$437.74
86147		<1%	12	$425.56
36415	Collection of venous blood by venipuncture	<1%	3,696	$420.22
82270		<1%	252	$407.96
82565		<1%	130	$372.54
82977		<1%	99	$368.16
86310		<1%	104	$368.01
81000		<1%	219	$351.16
82310		<1%	129	$336.91
86677		<1%	31	$308.99
87205		<1%	111	$274.99
84425		<1%	14	$261.52
84520		<1%	126	$246.07
83876		<1%	16	$239.68
82272		<1%	178	$233.62
81005		<1%	243	$229.91
84132		<1%	127	$215.49
86037		<1%	17	$202.81
84446		<1%	17	$201.96
84295		<1%	126	$192.64
82378		<1%	27	$182.99
86036		<1%	14	$167.02
86141		<1%	39	$166.53
82435		<1%	128	$166.41
80164		<1%	16	$154.48
84460		<1%	26	$108.72
84681		<1%	13	$106.62
86304		<1%	13	$92.14
87338		<1%	16	$87.47
82374		<1%	130	$81.20
86403		<1%	12	$56.57
80051		<1%	12	$49.60
86774		<1%	12	$26.17
99199	Unlisted special service, procedure or report	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.